Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer

Cytokine

Volumn 61, Issue 1, 2013, Pages 223-227

  Yousif, Nasser Ghaly ^a   Al amran, Fadhil G ^a,b   Hadi, Najah ^b   Lee, Jillen ^a   Adrienne, Jonthan ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF KUFA   (Iraq)

Author keywords

Cytokines; Esophageal cancer; IL 32; NF B; P p38 MAPK

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ESOPHAGUS CANCER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

AGED; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; INTERLEUKINS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869872590     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.09.022     Document Type: Article

References (32)

1. Torek, F The first successful resection of the thoracic portion of the esophagus for carcinoma. Surg Gynecol Obstet 1913, 16:614-617.
2. Dahl C.A., Schall R.P., He H.L., Cairns J.S. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992, 148:597-603.
3. Goda C., Kanaji T., Kanaji S., Tanaka G., Arima K., Ohno S., et al. Involvement of IL-32 in activation-induced cell death in T cells. Int Immunol 2006, 18:233-240.
4. Kim S.H., Han S.Y., Azam T., Yoon D.Y., Dinarello C.A. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity 2005, 22:131-142.
5. Shioya M., Nishida A., Yagi Y., Ogawa A., Tsujikawa T., Kim-Mitsuyama S., et al. Clin Exp Immunol 2007, 149:480-486.
6. Calabrese F., Baraldo S., Bazzan E., Lunardi F., Rea F., Maestrelli P., et al. IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 178:894-901.
7. Kim K.H., Shim J.H., Seo E.H., Cho M.C., Kang J.W., Kim S.H., et al. J Immunol Methods 2008, 333:38-50.
8. Atsushi Nishida, Akira Andoh1, Osamu Inatomi, Yoshihide Fujiyama. 2009, JBC vol. 284(26).
9. Baldwin A.S. The NF-κB and IκB proteins: new discoveries and insights. Ann Rev Immunol 1996, 14:649-683.
10. Tai D.-I., Tsai S.-L., Chang Y.-H., et al. Constitutive activation of nuclear factor B in hepatocellular carcinoma. Cancer 2000, 89:2274-2281.
11. Nguyen D.M., Chen G.A., Reddy R., et al. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. J Thorac Cardiovasc Surg 2004, 127:365-375.
12. Li J., Minnich D.J., Camp E.R., et al. Enhanced sensitivity to chemotherapy in esophageal cancer through inhibition of NF-κB. J Surg Res 2006, 132:112-120.
13. Olson J.M., Hallahan A.R. P38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004, 10:125-129.
14. Rincon M., Davis R.J. Regulation of the immune response by stress-activated protein kinases. Immunol. Rev. 2009, 228:212-224.
15. Bulavin D.V., Fornace A.J. P38 MAP kinase's emerging role as a tumor suppressor. Adv. Cancer Res. 2004, 92:95-118.
16. Puri P.L., Wu Z., Zhang P., Wood L.D., Bhakta K.S., Han J., et al. Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 2000, 14:574-584.
17. Sorrentino C., Scarinci A., D'Antuono T., Piccirilli M., Di Nicola M., Pasquale M., et al. Endomyocardial infiltration by B and NK cells foreshadows the recurrence of cardiac allograft rejection. J Pathol 2006, 209(400-410):18.
18. Adachi t, Choudhury K., Stafford S., Sur S., Alam R. The differential role of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000, 165:2198-2204.
19. Lee S., Kim S., Bae S., Choi J., Hong J., Ryoo S., et al. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA. Hybridoma 2010, 29:501-509.
20. Chaturvedi M.M., Mukhopadhyay A., Aggarwal B.B. Assay for redoxsensitive transcription factor. Meth Enzymol 2000, 319:585-602.
21. Andoh A., Takaya H., Saotome T., Shimada M., Hata K., Araki Y., et al. Gastroenterology 2000, 119:211-219.
22. Netea M.G., Azam T., Ferwerda G., Girardin S.E., Walsh M., Park J.S., et al. Proc. Natl. Acad. Sci. USA 2005, 102:16309-16314.
23. Joosten L.A., Netea M.G., Kim S.H., Yoon D.Y., Oppers-Walgreen B., Radstake T.R., et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006, 103:3298-3303.
24. Shioya M., Nishida A., Yagi Y., Ogawa A., Tsujikawa T., Kim-Mitsuyama S., et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007, 149:480-486.
25. Marcondes A.M., Mhyre A.J., Stirewalt D.L., Kim S.H., Dinarello C.A., et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci U S A 2008, 105:2865-2870.
26. Kobayashi H., Huang J., Ye F., Shyr Y., Blackwell T.S., Lin P.C. Interleukin-32β propagates vascular inflammation and exacerbates sepsis in a mouse model. Plos One 2010, 5:9458.
27. Dejardin E., Deregowski V., Chapelier M., et al. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999, 18:2567-2577.
28. Mohamed M. M. Abdel-Latif, James O'Riordan, Henry J. Windle, Eleanor Carton, Nagunivan Ravi, Dermot Kelleher, and John V. Reynolds, Ann Surg. 2004, 239(4):491-500.
29. Carlo Sorrentino1,2, Emma Di Carlo1,2. Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype, Am J Respir Crit Care Med 180: 2009;769-79.
30. Zhang Qian.-Xian., Feng Ruo., Zhang Wei., Ding Yi., Yang Ji.-Yao., Liu Guo.-Hong. Role of stress-activated MAP kinase P38 in cisplatin- and DTT-induced apoptosis of the esophageal carcinoma cell line Eca109. World J Gastroenterol 2005, 11(29):4451-4456.
31. Viktorsson K., Ekedahl J., Lindebro M.C., Lewensohn R., Zhivotovsky B., Linder S., et al. Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line. Exp Cell Res 2003, 289:256-264.
32. Mansouri A., Ridgway L.D., Korapati A.L., Zhang Q., Tian L., Wang Y., et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003, 278:19245-19256.